Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
Novel Anti-Inflammatory and Immunomodulatory Agents Based On Oleyl Alcohols
Yeda R&D Co. Ltd Israel flag Israel
Abstract ID: 1280
Anti-inflammatory agents that modulate the inflammatory response were found to be effective in a wide variety of pathological conditions. Anti-inflammatory agents are usually classified as steroidal or glucocorticoids...
Contact
Participants
You
Email me a copy of this message
Introduction/Background

Anti-inflammatory agents that modulate the inflammatory response were found to be effective in a wide variety of pathological conditions. Anti-inflammatory agents are usually classified as steroidal or glucocorticoids and nonsteroidal anti-inflammatory agents (NSAIDs). The glucocorticoids are powerful anti-inflammatory agents but their chronic administration often leads to high toxicity.

Aims/Hypothesis

Therefore, it would be highly desirable to provide new NSAIDs that could serve as alternatives to current anti-inflammatory drugs.

Research

The most advanced new chemical entity (OA-1) derived from the outlined technology has been designed to treat psoriasis and other inflammatory skin diseases. The therapeutic effects of this molecule are equivalent to those produced by glucocorticoids but without the associated side effects.

The pathogenesis of immunologically-mediated inflammation disorders is tightly linked to the activation of T-cell lymphocytes. The mechanism of action of OA-1 involves the blockade of T-cell anti-inflammatory cytokine secretion, including IFNgamma and TNFalpha. This drug, administered topically as an emulsion in a balanced salt solution, has been shown to be effective in animal models of delayed hypersensitivity and in a model of psoriasis in which the disease is expressed in human psoriatic skin transplanted onto SCID mice. Other animal studies showed efficacy in other inflammatory models such as Adjuvant-Arthritis. Toxicology studies in preparation for human phase I trials are at an advanced stage.

Conclusion

We have elucidated oleyl alcohol with anti-inflammatory effects that may be chemically tailored for particular medical applications.

Relevance/Opportunity

OA is suitable for treatment of psoriasis and other inflammatory skin problems. Please enquire quoting reference no. 1280 regarding licensing or codevelopment partnerships.
GO PREMIUM TO GET PATENT INFORMATION
FEATURED
Last Updated May 2015
Technology Type THERAPEUTIC
Phase of Development PRECLINICAL
CORPORATION